Compare BNR & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNR | CIK |
|---|---|---|
| Founded | 2014 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.5M | 127.8M |
| IPO Year | 2019 | 1995 |
| Metric | BNR | CIK |
|---|---|---|
| Price | $13.00 | $2.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.4K | ★ 411.9K |
| Earning Date | 11-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $101.46 | N/A |
| Revenue Next Year | $14.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.79 | $2.26 |
| 52 Week High | $41.72 | $2.88 |
| Indicator | BNR | CIK |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 53.54 |
| Support Level | $9.12 | $2.26 |
| Resistance Level | $19.10 | $2.40 |
| Average True Range (ATR) | 1.26 | 0.03 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 88.67 | 65.38 |
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.